Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This study will combine cabozantinib with pemetrexed to treat patients with non-small cell
lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the
safety of both drugs used together and see what effect (good or bad) it has no participants
and their cancer.